TWINRIX

Adapted from the TWINRIX Product Monograph. Please refer to the Product Monograph for additional immunogenicity data.

* Clinical significance is unknown.
† A booster dose is recommended 12 months after administration of the first dose.
‡ Rapid dosing is recommended only for adults, when travel is anticipated within one month or more after initiating the vaccination course, but where insufficient time is available to allow the standard schedule to be completed. 1

TWINRIX anti-HBV seroprotection rates

TWINRIX anti-HBV response rates in adults*

Adapted from the TWINRIX Product Monograph. Please refer to the Product Monograph for additional immunogenicity data.

* Clinical significance is unknown.
† Represents anti-HBV seroconversion rate in adult subjects.
‡ Rapid dosing is recommended only for adults, when travel is anticipated within one month or more after initiating the vaccination course, but where insufficient time is available to allow the standard schedule to be completed.
§ A booster dose is recommended 12 months after administration of the first dose.

TWINRIX combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine is indicated for active immunization against hepatitis A and hepatitis B virus infection in adults, adolescents, children and infants. TWINRIX will not protect against infection caused by other agents such as hepatitis C, hepatitis E and other pathogens known to infect the liver. It can be expected that hepatitis D will also be prevented by immunization with TWINRIX as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection. 1